Nurix Therapeutics (NRIX) Return on Equity (2020 - 2026)

Nurix Therapeutics (NRIX) has 7 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, changed 0.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Equity was little changed at 0.01% in Q1 2026 per NRIX's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 0.0% in Q1 2025 and troughed at 0.01% in Q1 2024.
• A 5-year average of 0.01% and a median of 0.01% in 2026 frame the typical range for Return on Equity.
• On a YoY basis, Return on Equity climbed as much as 0 bps in 2022 and fell as far as 0 bps in 2022.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then declined by 19 bps to 0.01% in 2023, then jumped by 35 bps to 0.0% in 2024, then plunged by 36 bps to 0.01% in 2025, then grew by 0 bps to 0.01% in 2026.
• Business Quant data shows NRIX's Return on Equity at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.